

News

Copenhagen, November 26, 2020

2cureX launches new website

Copenhagen, November 26, 2020 – 2cureX is proud to announce the launch of its newly redesigned website at <https://www.2curex.com/>. The new site features a streamlined, modern design and improved functionality.

The primary goal during the redesign process was to create a more valuable, user-centric and responsive resource across all platforms and devices. Specifically, the primary aim of the development of the improved website was to make it easier for a broader group of users to learn and locate valuable information about our IndiTreat test, clinical programs, important projects and activities.

CEO Ole Thastrup states: *"2cureX entered a new important phase where the focus is on commercializing the IndiTreat® test towards our customers, influencers and commercial partners. I believe that we made an important step forward and that the new look and feel of 2cureX.com reflects our ambition to improve patient outcomes for Cancer Patients"*

Keep up to date by subscribing to our newsletter to receive our news, activities and company announcements <https://www.2curex.com/contact/>.

For any suggestions, questions, comments please contact 2cureX.

For more information about 2cureX, please contact:

Ole Thastrup, CEO
E-post: ot@2curex.com
Telefon: +45 22 11 53 99
www.2curex.com

Certified Adviser
Redeye AB
Telefon: +46 8 121 576 90
E-mail: certifiedadviser@redeye.se

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient's tumor and identifies the treatment that most effectively kills the patient's tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany, Sweden and United Kingdom.

IndiTreat® is presently being marketed into the European market.

The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX").